Cargando…

Post-COVID-19 psychiatric and cognitive morbidity: Preliminary findings from a Brazilian cohort study

OBJECTIVE: The present study aims to investigate the occurrence of psychiatric and cognitive impairments in a cohort of survivors of moderate or severe forms of COVID-19. METHOD: 425 adults were assessed 6 to 9 months after hospital discharge with a structured psychiatric interview, psychometric tes...

Descripción completa

Detalles Bibliográficos
Autores principales: Damiano, Rodolfo Furlan, Caruso, Maria Julia Guimarães, Cincoto, Alissom Vitti, de Almeida Rocca, Cristiana Castanho, de Pádua Serafim, Antonio, Bacchi, Pedro, Guedes, Bruno F., Brunoni, André R., Pan, Pedro Mario, Nitrini, Ricardo, Beach, Scott, Fricchione, Gregory, Busatto, Geraldo, Miguel, Euripedes Constantino, Forlenza, Orestes V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8734055/
https://www.ncbi.nlm.nih.gov/pubmed/35134702
http://dx.doi.org/10.1016/j.genhosppsych.2022.01.002
Descripción
Sumario:OBJECTIVE: The present study aims to investigate the occurrence of psychiatric and cognitive impairments in a cohort of survivors of moderate or severe forms of COVID-19. METHOD: 425 adults were assessed 6 to 9 months after hospital discharge with a structured psychiatric interview, psychometric tests and a cognitive battery. A large, multidisciplinary, set of clinical data depicting the acute phase of the disease, along with relevant psychosocial variables, were used to predict psychiatric and cognitive outcomes using the ‘Least Absolute Shrinkage and Selection Operator’ (LASSO) method. RESULTS: Diagnoses of ‘depression’, ‘generalized anxiety disorder’ and ‘post-traumatic stress disorder’ were established respectively in 8%, 15.5% and 13.6% of the sample. After pandemic onset (i.e., within the previous year), the prevalence of ‘depression’ and ‘generalized anxiety disorder’ were 2.56% and 8.14%, respectively. Memory decline was subjectively reported by 51.1% of the patients. Psychiatric or cognitive outcomes were not associated with any clinical variables related to the severity of acute-phase disease, nor by disease-related psychosocial stressors. CONCLUSIONS: This is the first study to access rates of psychiatric and cognitive morbidity in the long-term outcome after moderate or severe forms of COVID-19 using standardized measures. As a key finding, there was no significant association between clinical severity in the acute-phase of SARS-CoV-2 infection and the neuropsychiatric impairment 6 to 9 months thereafter.